

Aurora Europe Celebrates First Continental Shipment of Medical Cannabis

Inaugural 'Made-in-Europe' high-quality EU GMP product bound for German pharmacies

Berlin, November 25, 2020 – Aurora Europe, a leading producer and distributor of medical cannabis, announced its first shipment of European produced supply of EU Good Manufacturing Practice certified medical cannabis to the German market. The first batch of dried flower medical cannabis comes from Aurora Nordic, a subsidiary of Aurora Cannabis Inc., which is a high-tech cultivation facility in Odense, Denmark. This shipment marks a significant milestone for the company and its expanded supply solution for the fast-moving European medical cannabis market. With more than 9,200 m² production space and an output of approximately 10,000 kg of high-quality medical cannabis per year, the Aurora Nordic facility is well positioned to service European and international markets.

"Our first product delivered to Germany from continental production is a key milestone for Aurora in Europe, after having spent two years building and licencing an innovative production facility. We are very proud that we can provide patients with high-quality medical cannabis, delivered directly from Aurora's first greenhouse facility on European soil," says Dr. Axel Gille, President of Aurora Europe.

Aurora Nordic recently received its European Union Good Manufacturing Practice certification by the Danish Medicines Agency (*Lægemiddel-styrelsen*) of the Danish Health Authority (*Sundhedsstyrelsen*). The EU GMP certification recognizes superior levels of quality in both products and services. This crucial step allows Aurora to manufacture and export EU GMP-certified medical cannabis products from Denmark to other European markets in accordance with local medical cannabis regulations. Dried flower will be the first of several products exported from the Danish facility, with expanded product offerings expected to follow in the near term.

Germany was one of the first European countries to legalize medical cannabis and is currently Europe's largest market. The market has experienced a steady rate of growth, evidenced by the doubling of medical cannabis prescriptions from 2018 – 2019. Aurora intends to leverage Aurora Nordic as a continental benefit to further unlock value in key growth markets.

About Aurora Europe

Aurora Europe, headquartered in Berlin, Germany, is a subsidiary of Aurora Cannabis Inc., a global leader in the cannabis industry serving both medical and consumer markets and dedicated to helping people improve their lives. Aurora Europe supplies high-quality medical cannabis products to patients throughout Europe. In 2015, Aurora entered the German market and today operates one of the largest authorised importers and distributors of medical cannabis in Europe. Aurora's internal network of EU GMP facilities continues to bring high-quality, premium medical cannabis to patients worldwide.

Media Contact:

Yvonne Moeller | Director Communications Europe

Aurora Europe GmbH | Wilmersdorfer Straße 98/99 | 10629 Berlin

M +49 (0) 176 18000 560 | T +49 (0)30 9832 1601 0

yvonne.moeller@auroramedicine.com | www.auroramedicine.com